It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Discover precise insights into brain neurochemistry with Sygnature Discovery's in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.
scientific solutions
Sygnature Discovery delivers world-class scientific expertise and flexible services across every discipline in drug discovery.
Our scientists work as an extension of your team, powered by AI, automation, and a shared commitment to your success. We are ready to partner with you, from targeted project support to fully integrated discovery programs.
fully integrated drug discovery hubs in UK and North America
60 +
novel pre-clinical and 35+ clinical compounds delivered since 2011
Supporting Your Research
At Sygnature Discovery, we support every stage of drug discovery, offering specialist services that adapt to your needs whether you’re solving a specific challenge or running a full discovery program.
Our highly skilled scientists work as an extension of your team, combining deep expertise in the core drug discovery disciplines with AI, machine learning, and automation to deliver faster, smarter results.
We offer standalone and integrated scientific solutions across bioscience, protein science & structural biology, medicinal chemistry, computer-aided drug design (CADD), drug metabolism & pharmacokinetics (DMPK), form & formulation, and in vivo pharmacology.
Whether you need focused support for a specific challenge, or specialist input to complement your internal capabilities, we tailor our approach to your goals. With Sygnature, you gain more than a service provider, you gain a trusted scientific partner committed to delivering meaningful results and advancing your high-quality candidates to clinic.
Our Scientific Solutions
We provide flexible access to exceptional scientific talent, tailored to projects of any size or complexity. Our scientists are supported by advanced AI tools that streamline workflows and improve decision-making. Whether you’re solving a specific challenge or scaling up a program, we deliver agile, high-impact solutions that move your science forward.
Computer Aided Drug Design (CADD)
Our team draws on decades of experience to help you design smarter compounds and make faster decisions by combining AI-powered modeling, scientific expertise, and secure, collaborative data access. We solve complex challenges and accelerate your drug discovery journey.
With over 65 protein scientists at Sygnature Discovery globally, we take pride in providing high quality, fully characterized proteins for a wide range of applications such as enzymatic assays, in vivo studies, diagnostic kits, biotherapeutics, crystallography, cryo-EM and more.
Our in-depth knowledge of target biology, therapeutic area expertise and experience of working collaboratively at each stage of the drug discovery pipeline allows the efficient design and implementation of tailored high-quality assays, which help to accelerate your drug discovery programs.
From design to clinic, Sygnature Discovery’s global chemistry team partners with you to deliver molecules that matter by overcoming complexity, optimizing molecular properties, and accelerating discovery. Our dedicated project leaders and chemists work alongside you, co-designing strategies and guiding decisions.
At Sygnature Discovery, our integrated in vitro and in vivo DMPK platforms provide mechanistic insight and predictive data that support rational design and informed decision-making, from hit identification through to candidate nomination.
From candidate selection to clinic, we partner with you to design smart, scalable formulations built on solid-state insight, multidisciplinary expertise, and a shared commitment to scientific success.
Bridging the gap between scientific innovation and patient impact, we deliver high-quality, clinically relevant in vivo data that drives faster, smarter decisions through tailored study designs, advanced technologies, and close collaboration across disciplines, improving project outcomes and maximizing clinical relevance.
Drug discovery is evolving, and so are the challenges. As global health demands rise, the need for smarter, faster, and more connected science has never been greater. Yet too often, progress is slowed by disconnection between disciplines and data.
At Sygnature Discovery, our aim is to reshape how drug discovery is delivered. Through flexible services and integrated expertise, we enable innovation at every stage. With AI and automation embedded across our workflows, we help you move faster and make confident decisions, delivering results with confidence and integrity.
Whether we’re supporting you through the entire process or just a part of it, our goal isn’t simply to move you to the next stage, it’s to lay the foundations for a successfully marketed drug.
Choosing Sygnature Discovery means partnering with over 700 talented scientists from 50 countries, all focused on your priorities. With no internal drug programs, our sole focus is your success, ensuring total confidentiality and dedicated expertise.
Our co-located teams across the UK and North America collaborate to deliver data-driven, transparent, and rigorous science powered by AI and grounded in integrity. With 60+ candidates advanced since 2011 and many repeat customers, we’re trusted by partners worldwide to deliver excellence, whether for a single study or a strategic program.
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
Focusing on the craving phase of addiction, this article examines how behavioral pharmacology models capture cue‑driven drug seeking and relapse vulnerability.
Focusing on the withdrawal phase of addiction, this article examines how behavioral pharmacology models assess drug dependence and therapeutic intervention in preclinical studies.
Focusing on the intoxication phase of addiction, this article examines how behavioral pharmacology models capture reward, reinforcement and binge‑like drug use in preclinical studies.
Drug addiction remains one of the most persistent and complex public health challenges worldwide. Despite advances in prevention and treatment, drug‑related harm and mortality continue to rise, underscoring the need for deeper biological understanding and more predictive models to support the development of new therapies.
Blog
An error has occurred, please try again later.An error has occurred, please try again later.
You're in the right place!
Peak Proteins, NuChem Sciences, and SB Drug Discovery have now fully integrated with Sygnature Discovery.
